Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Sell
34
WST Quote, Financials, Valuation and Earnings
Last price:
$205.72
Seasonality move
:
3.44%
Day range:
$209.81 - $213.34
52-week range:
$187.43 - $372.52
Dividend yield:
0.39%
P/E ratio:
33.12x
P/S ratio:
5.35x
P/B ratio:
5.65x
Volume:
439.3K
Avg. volume:
977.6K
1-year change:
-42.2%
Market cap:
$15.2B
Revenue:
$2.9B
EPS (TTM):
$6.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$687.4M | $1.26 | 3.28% | -0.47% | $281.83 |
|
BAX
Baxter International
|
$2.6B | $0.48 | -25.96% | 590.29% | $38.68 |
|
BDX
Becton Dickinson &
|
$5.4B | $3.28 | 10.23% | 104.55% | $225.25 |
|
BSX
Boston Scientific
|
$4.6B | $0.67 | 18.78% | 229.2% | $116.12 |
|
RMD
ResMed
|
$1.3B | $2.36 | 8.17% | 24.05% | $264.49 |
|
TFX
Teleflex
|
$699.4M | $2.88 | 2.91% | 98.97% | $157.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$210.98 | $281.83 | $15.2B | 33.12x | $0.21 | 0.39% | 5.35x |
|
BAX
Baxter International
|
$30.43 | $38.68 | $15.6B | 167.20x | $0.17 | 3.02% | 1.31x |
|
BDX
Becton Dickinson &
|
$167.00 | $225.25 | $47.9B | 31.87x | $1.04 | 2.38% | 2.32x |
|
BSX
Boston Scientific
|
$104.24 | $116.12 | $154.2B | 76.09x | $0.00 | 0% | 8.84x |
|
RMD
ResMed
|
$240.66 | $264.49 | $35.3B | 27.01x | $0.53 | 0.86% | 7.07x |
|
TFX
Teleflex
|
$122.90 | $157.62 | $5.4B | 38.77x | $0.34 | 1.11% | 1.91x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
7.02% | 0.860 | 1.26% | 1.80x |
|
BAX
Baxter International
|
65.34% | 0.052 | -- | 0.54x |
|
BDX
Becton Dickinson &
|
43.29% | 0.098 | 29.35% | 0.48x |
|
BSX
Boston Scientific
|
33.49% | 1.029 | 7.48% | 0.68x |
|
RMD
ResMed
|
10.82% | 0.505 | 2.05% | 1.99x |
|
TFX
Teleflex
|
31.78% | 0.827 | 30.89% | 1.11x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$231.9M | $127.6M | 16.23% | 17.47% | 15.89% | $58.1M |
|
BAX
Baxter International
|
$861M | $58M | -2.68% | -8.24% | 2.32% | $351M |
|
BDX
Becton Dickinson &
|
$2.3B | $637M | 3.35% | 5.86% | 9.75% | $35M |
|
BSX
Boston Scientific
|
$3.2B | $937M | 6.35% | 9.57% | 19.02% | $277M |
|
RMD
ResMed
|
$766.4M | $426.3M | 22.47% | 25.76% | 33% | $554.9M |
|
TFX
Teleflex
|
$389.4M | $130.3M | 2.43% | 3.41% | 18.2% | $43.1M |
West Pharmaceutical Services vs. Competitors
-
Which has Higher Returns WST or BAX?
Baxter International has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 4.8%. West Pharmaceutical Services's return on equity of 17.47% beat Baxter International's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B BAXBaxter International32.8% $0.25 $20.2B -
What do Analysts Say About WST or BAX?
West Pharmaceutical Services has a consensus price target of $281.83, signalling upside risk potential of 33.58%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 27.11%. Given that West Pharmaceutical Services has higher upside potential than Baxter International, analysts believe West Pharmaceutical Services is more attractive than Baxter International.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 2 0 BAXBaxter International4 11 1 -
Is WST or BAX More Risky?
West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.
-
Which is a Better Dividend Stock WST or BAX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Baxter International offers a yield of 3.02% to investors and pays a quarterly dividend of $0.17 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BAX?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Baxter International quarterly revenues of $2.6B. West Pharmaceutical Services's net income of $89.8M is lower than Baxter International's net income of $126M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.12x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.35x versus 1.31x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.35x 33.12x $698M $89.8M BAXBaxter International1.31x 167.20x $2.6B $126M
-
Which has Higher Returns WST or BDX?
Becton Dickinson & has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 5.84%. West Pharmaceutical Services's return on equity of 17.47% beat Becton Dickinson &'s return on equity of 5.86%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B BDXBecton Dickinson &42.81% $1.07 $44.5B -
What do Analysts Say About WST or BDX?
West Pharmaceutical Services has a consensus price target of $281.83, signalling upside risk potential of 33.58%. On the other hand Becton Dickinson & has an analysts' consensus of $225.25 which suggests that it could grow by 34.88%. Given that Becton Dickinson & has higher upside potential than West Pharmaceutical Services, analysts believe Becton Dickinson & is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 2 0 BDXBecton Dickinson &5 10 0 -
Is WST or BDX More Risky?
West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.312, suggesting its less volatile than the S&P 500 by 68.788%.
-
Which is a Better Dividend Stock WST or BDX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Becton Dickinson & offers a yield of 2.38% to investors and pays a quarterly dividend of $1.04 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BDX?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Becton Dickinson & quarterly revenues of $5.3B. West Pharmaceutical Services's net income of $89.8M is lower than Becton Dickinson &'s net income of $308M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.12x while Becton Dickinson &'s PE ratio is 31.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.35x versus 2.32x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.35x 33.12x $698M $89.8M BDXBecton Dickinson &2.32x 31.87x $5.3B $308M
-
Which has Higher Returns WST or BSX?
Boston Scientific has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 14.45%. West Pharmaceutical Services's return on equity of 17.47% beat Boston Scientific's return on equity of 9.57%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B BSXBoston Scientific68.84% $0.45 $33.6B -
What do Analysts Say About WST or BSX?
West Pharmaceutical Services has a consensus price target of $281.83, signalling upside risk potential of 33.58%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 11.4%. Given that West Pharmaceutical Services has higher upside potential than Boston Scientific, analysts believe West Pharmaceutical Services is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 2 0 BSXBoston Scientific23 4 0 -
Is WST or BSX More Risky?
West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.
-
Which is a Better Dividend Stock WST or BSX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BSX?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Boston Scientific quarterly revenues of $4.7B. West Pharmaceutical Services's net income of $89.8M is lower than Boston Scientific's net income of $674M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.12x while Boston Scientific's PE ratio is 76.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.35x versus 8.84x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.35x 33.12x $698M $89.8M BSXBoston Scientific8.84x 76.09x $4.7B $674M
-
Which has Higher Returns WST or RMD?
ResMed has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 28.26%. West Pharmaceutical Services's return on equity of 17.47% beat ResMed's return on equity of 25.76%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B RMDResMed59.33% $2.48 $6.2B -
What do Analysts Say About WST or RMD?
West Pharmaceutical Services has a consensus price target of $281.83, signalling upside risk potential of 33.58%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 9.9%. Given that West Pharmaceutical Services has higher upside potential than ResMed, analysts believe West Pharmaceutical Services is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 2 0 RMDResMed8 6 1 -
Is WST or RMD More Risky?
West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.
-
Which is a Better Dividend Stock WST or RMD?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or RMD?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than ResMed quarterly revenues of $1.3B. West Pharmaceutical Services's net income of $89.8M is lower than ResMed's net income of $365M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.12x while ResMed's PE ratio is 27.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.35x versus 7.07x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.35x 33.12x $698M $89.8M RMDResMed7.07x 27.01x $1.3B $365M
-
Which has Higher Returns WST or TFX?
Teleflex has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 13.56%. West Pharmaceutical Services's return on equity of 17.47% beat Teleflex's return on equity of 3.41%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B TFXTeleflex55.58% $2.07 $6B -
What do Analysts Say About WST or TFX?
West Pharmaceutical Services has a consensus price target of $281.83, signalling upside risk potential of 33.58%. On the other hand Teleflex has an analysts' consensus of $157.62 which suggests that it could grow by 28.25%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services10 2 0 TFXTeleflex0 11 0 -
Is WST or TFX More Risky?
West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Teleflex has a beta of 1.170, suggesting its more volatile than the S&P 500 by 17.034%.
-
Which is a Better Dividend Stock WST or TFX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.39%. Teleflex offers a yield of 1.11% to investors and pays a quarterly dividend of $0.34 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or TFX?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Teleflex quarterly revenues of $700.7M. West Pharmaceutical Services's net income of $89.8M is lower than Teleflex's net income of $95M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 33.12x while Teleflex's PE ratio is 38.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.35x versus 1.91x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.35x 33.12x $698M $89.8M TFXTeleflex1.91x 38.77x $700.7M $95M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Is RTX The Best Growth Stock?
Among the worldwide aerospace and defense markets, the US controls…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 156.24% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.02% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 6.35% over the past day.
